M6P Therapeutics Supports Rare Disease Day 2021 and Joins Global Movement to Increase Awareness of Rare Diseases

 M6P Therapeutics (“M6PT” or “the Company”), a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs), today announced its support for Rare Disease Day 2021 and commitment to the rare disease community. Rare Disease Day is an annual awareness day dedicated to elevating the public understanding of rare diseases and their impact on patients’ lives.

According to the National Institutes of Health, there are approximately 7,000 rare diseases affecting between 25 and 30 million Americans. In the U.S., a disease is defined as rare if it affects fewer than 200,000 people. Only 5% of the over 7,000 identified rare diseases have an FDA approved treatment.¹

In honor of Rare Disease Day 2021, M6P Therapeutics today hosted an all-company town hall meeting to highlight the importance of research in rare diseases, share patient stories and testimonials, and motivate and inspire the team as the company works to develop therapies to treat patients with LSDs. In recognition of the vital role of patient organizations in educating communities, empowering patients, and advancing research, M6P Therapeutics has given donations to several patient organizations within the LSD community.

“On Rare Disease Day, we celebrate the strength and perseverance of patients, families, and advocates living with rare diseases who seek to improve awareness, understanding, diagnosis, and treatment of these serious conditions,” said Pawel Krysiak, president and chief executive officer of M6P Therapeutics. “The goal of serving patients with lysosomal storage disorders guides our every decision at M6P Therapeutics, and we are committed to working in partnership with patient communities to develop next-generation therapies with the potential to improve lives.”